Safety evaluation of current therapies for high-risk severely ill patients with carbapenem-resistant infections

Abstract

Introduction: Infections due to carbapenem-resistant Gram-negative bacteria (CR-GNB) are increasingly frequent events, which are associated with a high mortality rate. Traditionally, combination regimens including high doses of "old antibiotics" such as polymyxins, tigecycline, and aminoglycosides have been used to treat these infections, but they were often associated with low efficacy and high excess of side effects and toxicity, especially nephrotoxicity. Along with the development of new compounds, the last decade has seen substantial improvements in the management of CR infections.

Areas covered: In this review, we aimed to discuss the safety characteristics and tolerability of different new options for treatment of CR infections.

Expert opinion: The availability of new drugs showing a potent in vitro activity against CR-GNB represents a unique opportunity to face the threat of resistance, while potentially reducing toxicity. A thorough understanding of the safety profile from clinical trials may guide the use of these new drugs in critically ill patients at high risk for the development of adverse events. Future data coming from real-life studies for drugs targeting CR infections are crucial to confirm the safety profile observed in pivotal trials.

Keywords: Carbapenem-resistant infections; acute kidney injury; carbapenemases; drug toxicity; new antibiotics.